Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

The Phase III trial AV001 aims to evaluate QUTENZA in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

- The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...

These included 186,144 people with epilepsy, 169,127 with peripheral neuropathy (PN), 60,861 with Alzheimer ... the ...

A joint presentation by an endocrinologist and ophthalmologist reviewed best practices for managing thyroid eye disease, ...

Chemotherapy for three months demonstrates lower side effects, suggesting its use as standard care compared with six months.

Report on how AI is redefining market landscape - The global gastroparesis drugs market  size is estimated to grow by USD 1.42 billion from 2024-2028, according to Technavio. The market is estimated ...

However, as for traditional chemotherapy, ADCs can also induce treatment resistance and side effects such as neuropathy.

Suneeta’s research centers on identifying novel molecular signatures and biomarkers to improve the efficacy of cancer ...

Diabetes is a lifelong condition that causes your blood sugar levels to become too high - and some of the warning signs can appear in the feet. Here are the symptoms to look out for ...

Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments. One of these, lecanemab ...